Enveric Biosciences Inc. logo

Enveric Biosciences Inc.

ENVB | NASDAQ
Chart Builder DCF Calculator
$1.54
-$0.02 (-1.28%)
At close: Sep 22, 2026, 4:00 PM ET
$1.59
+$0.05 (+3.25%)
After-hours: Sep 22, 2026, 7:30 PM ET

Company Profile

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

Key Executives

Name Position
Joseph Edward Tucker Chief Executive Officer & Director
Kevin Coveney Chief Financial Officer
Peter J. Facchini Chief Innovation Officer

Latest SEC Filings

Date Type Title
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 09, 2026 8-K Current Report
Jun 09, 2026 424B5 Filing
Jun 09, 2026 8-K Current Report
Jun 01, 2026 S-8 Filing
May 29, 2026 8-K Current Report
View All SEC Filings
Enveric Biosciences Inc.
Enveric Biosciences Inc. logo
Country United States
IPO Date May 3, 2015
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Joseph Edward Tucker

Contact Details

245 First Street Cambridge, Massachusetts 02142 United States

Stock Details

Ticker Symbol ENVB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000890821
CUSIP Number 29405E505
ISIN Number US29405E5050
SIC Code 2834

© 2026 bestshares.com. All rights reserved.